Skip to main content
NCBI home page
Nature Communications logoLink to Nature Communications
. 2023 Jan 19;14:333. doi: 10.1038/s41467-023-35835-3

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Kara W Chew 1,✉, Carlee Moser 2, Eric S Daar 3, David A Wohl 4, Jonathan Z Li 5, Robert W Coombs 6,7, Justin Ritz 2, Mark Giganti 2, Arzhang Cyrus Javan 8, Yijia Li 5,14, Manish C Choudhary 5, Rinki Deo 5, Carlos Malvestutto 9, Paul Klekotka 10, Karen Price 10, Ajay Nirula 10, William Fischer 4, Veenu Bala 11,15, Ruy M Ribeiro 12, Alan S Perelson 12, Courtney V Fletcher 11, Joseph J Eron 4, Judith S Currier 1; ACTIV-2/A5401 Study Team, Michael D Hughes 2, Davey M Smith 13
PMCID: PMC9851732  PMID: 36658128

Correction to: Nature Communications 10.1038/s41467-022-32551-2, published online 22 August 2022

The original version of this article contained an error in the Abstract, which incorrectly omitted from the end the following: ‘Trial Registration: ClinicalTrials.gov Identifier: NCT04518410’. This has been corrected in both the PDF and HTML versions of the Article.

Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES